Postpartum Readmissions Shift as Diabetes-Related Admissions Decline and Overall Returns Rise
Postpartum hospitalization patterns changed in two directions at once between 2016 and 2022. Among women with gestational diabetes mellitus and among women without diabetes, all-cause readmissions rose by 30 days after delivery, yet readmissions tied to severe maternal morbidity and diabetes-related diagnoses generally fell across the same window. The dual trend matters because it separates overall utilization from complications that are more directly linked to metabolic disease and obstetric risk. It also suggests that some of the most dangerous postpartum events may be becoming less common even as hospitals still see more women back on the ward for other reasons.
Using the National Readmissions Database, investigators tracked women aged 15 to 44 years who delivered a live birth or stillbirth during the first half of each year from 2016 through 2022. They grouped births by diabetes status: GDM, pregestational diabetes mellitus, and no diabetes diagnosis. Readmissions were then examined at 30, 60, and 180 days postpartum, with attention to all-cause rehospitalization, severe maternal morbidity, diabetes-related diagnoses, mental health-related diagnoses, repeated admissions, and the leading reasons for return. A joinpoint approach was used to measure trends over time.
The pattern for all-cause readmissions was straightforward and unsettling. By 30 days postpartum, rates increased significantly among women with GDM and among women without diabetes, with an annual percent change of 2.78 in both groups. Even in a population where one might expect the sharpest risk to cluster around women with established diabetes, the broader postpartum system was pulling more patients back for any reason. In practical terms, that means the postpartum period remains clinically unstable even when diabetes itself is not the dominant driver of the readmission.
A different signal emerged when the endpoint narrowed to severe maternal morbidity. Rates of postpartum SMM readmissions declined significantly among women with GDM at 30, 60, and 180 days postpartum, with annual percent changes of -7.44, -7.12, and -6.37, respectively. Among women with pregestational diabetes, SMM readmissions fell by 60 days postpartum with an annual percent change of -7.05. Women without diabetes also showed declining SMM readmissions at 30, 60, and 180 days, with annual percent changes of -5.83, -5.68, and -4.45. Those downward slopes suggest fewer catastrophic postpartum complications across the board, not just in the diabetes-defined groups.
A second encouraging trend appeared in diabetes-related readmissions. Rates decreased across all measured postpartum periods among women with GDM and among women without diabetes, with statistical significance indicated by APC p values below .05. Among women with pregestational diabetes, diabetes-related readmissions also fell by 180 days postpartum, with an annual percent change of -7.03. Repeated diabetes-related admissions declined at 60 and 180 days postpartum in the pregestational diabetes group. The biology here is intuitive: tighter glycemic management, more structured inpatient and outpatient follow-up, and earlier recognition of decompensation can reduce the cascade that leads to recurrent admissions for hyperglycemia, infection, or diabetes-linked instability.
One sentence captures the tension in the data. Overall readmissions went up, but the diabetes-driven admissions that carry the greatest maternal danger went down.
Hypertensive disorders remained among the top three reasons for readmission regardless of diabetes status. That finding is clinically important because it points beyond glucose metabolism and toward vascular and placental pathology that often persists after delivery. Pregnancy-related hypertension, preeclampsia, and related syndromes can worsen after birth, especially when blood pressure surveillance weakens once the pregnancy is over. In women with GDM and pregestational diabetes, that overlap is especially concerning because diabetes and hypertensive disease often travel together, amplifying endothelial dysfunction, renal stress, and risk for readmission.
Mental health-related diagnoses were included in the study’s outcome framework, but the summary does not provide trend estimates for those admissions. Even without those details, the inclusion of mental health as a tracked endpoint reflects an increasingly realistic postpartum model in which cardiometabolic complications and psychological health cannot be separated cleanly. For many women, especially those with complicated pregnancies, postpartum recovery is shaped by pain, fatigue, blood pressure instability, glycemic swings, and mood symptoms all at once.
The time horizon also matters. Thirty-day readmissions may capture the immediate aftermath of delivery, when wound issues, blood pressure crises, and glucose disruptions are most visible. Sixty- and 180-day windows extend into a period when outpatient follow-up should ideally stabilize risk, yet the data still showed meaningful declines in severe maternal morbidity and diabetes-related admissions over time. That suggests a partial improvement in postpartum safety, but not a full resolution of the structural vulnerabilities that send women back to the hospital.
For bedside care, the findings argue for closer monitoring of women with GDM and pregestational diabetes for hypertensive disorders after birth, even when glucose-related complications are easing. Delivery is not the endpoint of maternal risk. The postpartum period remains a clinically active phase in which blood pressure surveillance, diabetes follow-up, and readmission prevention need to be coordinated rather than treated as separate tasks.
Hypertension Emerges as a Persistent Postpartum Readmission Driver
The readmission profile points toward a shared postpartum hazard: vascular instability. Hypertensive disorders appearing among the leading causes of rehospitalization across all diabetes strata suggests that postpartum surveillance should not narrow too quickly to glycemic issues alone. Women with GDM may be discharged after delivery with less attention to blood pressure because the pregnancy-associated glucose abnormality has resolved on paper, yet the vascular risk can linger. In women with pregestational diabetes, the combination of chronic metabolic disease and pregnancy-related hypertensive burden can create a higher-risk recovery period than routine follow-up schedules may capture.
The data do not show every mechanism behind the trend, and they do not prove which care processes improved. They do show that fewer women were returning with severe maternal morbidity and diabetes-related diagnoses, while more were returning for any reason within 30 days. That split should prompt more precise postpartum triage, especially for women whose pregnancies were complicated by diabetes and who may benefit from earlier blood pressure checks, symptom review, and coordinated follow-up after discharge.
The study leaves one concrete clinical question open: how much of the remaining postpartum readmission burden can be prevented by better hypertension surveillance alone. The answer will determine whether future gains come from metabolic follow-up, cardiovascular monitoring, or both.